E06, A NATURAL ANTIBODY TARGETED TO OXIDIZED PHOSPHOLIPIDS, ATTENUATES CARDIAC ISCHEMIA REPERFUSION INJURY IN MICE

Ischemia reperfusion (I/R) injury accounts for up to 50% of the final myocardial infarction size despite successful percutaneous coronary intervention. No effective pharmacologic therapies exist in humans to reduce I/R injury. Monoclonal antibody (MAb) E06 binds to the phosphocholine (PC) head group